Cargando…

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia

PURPOSE: Children with acute myeloid leukemia (AML) whose disease is refractory to standard induction chemotherapy therapy or who experience relapse after initial response have dismal outcomes. We sought to comprehensively profile pediatric AML microRNA (miRNA) samples to identify dysregulated genes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Emilia L., Trinh, Diane L., Ries, Rhonda E., Wang, Jim, Gerbing, Robert B., Ma, Yussanne, Topham, James, Hughes, Maya, Pleasance, Erin, Mungall, Andrew J., Moore, Richard, Zhao, Yongjun, Aplenc, Richard, Sung, Lillian, Kolb, E. Anders, Gamis, Alan, Smith, Malcolm, Gerhard, Daniela S., Alonzo, Todd A., Meshinchi, Soheil, Marra, Marco A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2017
Materias:	Biology of Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721230/ https://www.ncbi.nlm.nih.gov/pubmed/29068783 http://dx.doi.org/10.1200/JCO.2017.74.7451

Ejemplares similares

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia
por: Marrero, Richard J., et al.
Publicado: (2023)

Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group
por: Nagarajan, Rajaram, et al.
Publicado: (2019)

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
por: Aplenc, Richard, et al.
Publicado: (2020)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival
por: Pommert, Lauren, et al.
Publicado: (2022)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
por: Huang, Benjamin J., et al.
Publicado: (2021)

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2015)

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2016)

Ethnic Variation of TET2 SNP rs2454206 and Association with Clinical Outcome in Childhood AML: A Report from the Children’s Oncology Group
por: Kutny, Matthew A., et al.
Publicado: (2015)

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia
por: Farrar, Jason E., et al.
Publicado: (2023)

Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia
por: Narayanan, P., et al.
Publicado: (2021)

Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022)

Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia
por: Huang, Benjamin J., et al.
Publicado: (2022)

Early discharge as a mediator of greater ICU‐level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report
por: Getz, Kelly D., et al.
Publicado: (2016)

Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group
por: Johnston, Donna, et al.
Publicado: (2015)

Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group
por: Vujkovic, Marijana, et al.
Publicado: (2016)

Merging Children’s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children’s Oncology Group
por: Li, Yimei, et al.
Publicado: (2015)

Endoscopic ultrasound in the assessment of advanced duodenal adenomatosis in familial adenomatous polyposis
por: Labib, Peter L, et al.
Publicado: (2019)

Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns
por: Dreval, Kostiantyn, et al.
Publicado: (2023)

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
por: McNeer, Nicole A., et al.
Publicado: (2019)

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial
por: Rafiee, Roya, et al.
Publicado: (2019)

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma
por: Thomas, Nicole, et al.
Publicado: (2023)

Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study
por: Joelsson, Joel, et al.
Publicado: (2022)

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
por: Epstein-Peterson, Zachary D., et al.
Publicado: (2022)

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531
por: Voigt, Andrew P., et al.
Publicado: (2017)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
por: Bhaskar, Shakthi T., et al.
Publicado: (2022)

Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia
por: Conneely, Shannon E., et al.
Publicado: (2021)

Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis
por: Ikeda, Masato, et al.
Publicado: (2022)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies
por: Herbst, Sophie A., et al.
Publicado: (2023)

Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness
por: Pirillo, Chiara, et al.
Publicado: (2022)

Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration
por: Hammer, Anne Sofie Borg, et al.
Publicado: (2022)

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
por: Burack, W. Richard, et al.
Publicado: (2023)

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
por: Gomez, Eliana B., et al.
Publicado: (2023)

Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma
por: Daenthanasanmak, Anusara, et al.
Publicado: (2022)

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement
por: Akin, Serkan, et al.
Publicado: (2022)

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
por: Dunbar, Andrew J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gp1ajieon57fnnbdhgsmobm4je